<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268333</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000453784</org_study_id>
    <secondary_id>GERCOR-C04-1</secondary_id>
    <secondary_id>EU-20568</secondary_id>
    <secondary_id>SANOFI-GERCOR-C04-1</secondary_id>
    <nct_id>NCT00268333</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase II Study of Recurrent Ganglionic Colorectal Cancer Not Accessible By Surgery Treated Using Chemotherapy With Simplified FOLFOX7 Followed By Radiotherapy Combined With 5FU and Oxaliplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
      Giving more than one drug (combination chemotherapy) together with radiation therapy may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with radiation therapy works in treating patients with recurrent metastatic colorectal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with recurrent metastatic colorectal cancer&#xD;
           treated with neoadjuvant oxaliplatin, fluorouracil, and leucovorin calcium followed by&#xD;
           radiotherapy and concurrent fluorouracil and oxaliplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall survival and disease-free survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the primary site of recurrence and time to recurrence in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, multicenter study.&#xD;
&#xD;
        -  Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours and leucovorin&#xD;
           calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously&#xD;
           over 46 hours beginning day 1. Treatment repeats every 14 days for 4 courses in the&#xD;
           absence of disease progression or unacceptable toxicity. Two to 5 weeks later, patients&#xD;
           with stable or responding disease proceed to chemoradiotherapy.&#xD;
&#xD;
        -  Chemoradiotherapy: Patients receive fluorouracil IV continuously 5 days a week for 5&#xD;
           weeks and oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29. Patients also undergo&#xD;
           radiotherapy 5 days a week for 5 weeks beginning on day 1.&#xD;
&#xD;
      Quality of life is assessed at baseline, 1 week after the completion of neoadjuvant&#xD;
      chemotherapy, on days 15, 30, and 42 of chemoradiotherapy, and at 1 and 2 months after the&#xD;
      completion of study treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary site of recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
               -  Metastatic disease isolated to the following lymph nodes:&#xD;
&#xD;
                    -  Aortic&#xD;
&#xD;
                    -  Interaortic&#xD;
&#xD;
                    -  Celiomesenteric&#xD;
&#xD;
                    -  Retroperitoneal, including the following sites:&#xD;
&#xD;
                         -  Peri-uretal&#xD;
&#xD;
                         -  Liver&#xD;
&#xD;
                         -  Iliac&#xD;
&#xD;
                         -  Clavicle&#xD;
&#xD;
                         -  Mediastinum&#xD;
&#xD;
                         -  Inguinal&#xD;
&#xD;
                         -  Cervical&#xD;
&#xD;
          -  Incompletely resected disease&#xD;
&#xD;
          -  Recurrent disease, defined by 1 of the following criteria:&#xD;
&#xD;
               -  Progression occurred within 6 months after prior oxaliplatin or after the patient&#xD;
                  received no prior oxaliplatin&#xD;
&#xD;
               -  Progressive disease after cisplatin or fluorouracil&#xD;
&#xD;
          -  Must be able to be encompassed in radiation field&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%&#xD;
&#xD;
          -  Life expectancy more than 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000 /mm^3&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 times normal&#xD;
&#xD;
          -  Bilirubin ≤ 2 times normal&#xD;
&#xD;
          -  Creatinine &lt; 2 times normal or creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No weight loss &gt; 15% since diagnosis of recurrent disease&#xD;
&#xD;
          -  No uncontrolled heart disease&#xD;
&#xD;
          -  No angina&#xD;
&#xD;
          -  No symptomatic disease of the inferior artery&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study treatment or compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Mineur, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Sainte Catherine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Drevon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique des Quatre Pavillons</name>
      <address>
        <city>Lormont</city>
        <zip>33310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique De Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>F-51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>December 20, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

